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ARTICLE OPEN ACCESS
Brainstem ischemic syndrome in juvenile NF2
John W. Henson, MD, FAAN, Tara Benkers, MD, and Connor McCormick, MD






A new case of brainstem ischemic necrosis in a young woman with de novo neurofibromatosis
type 2 (NF2) is reported, and given notable similarities to 7 prior cases of brainstem stroke in
the literature, features defining a possible syndrome were sought.
Methods
Case review including detailed clinical assessment, neuroimaging analysis, genetic testing, and
brain biopsy, followed by a multicase analysis.
Results
Brainstem ischemia in juvenile NF2 typically occurs in teenagers without previously known
NF2 as an acute, monophasic presentation with restricted diffusion in the midbrain or pons
following a recent hypoperfusion event, normal vascular imaging, obvious intracranial imaging
features of NF2, typical inactivating NF2 alterations, biopsy showing necrosis without small
vessel pathology, and subsequent aggressive NF2 lesion progression.
Conclusions
Brainstem ischemia in juvenile NF2 is a rare syndrome of unclear etiology, possibly reflecting an
unknown underlying vascular abnormality; a digenic effect is not excluded.
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Neurofibromatosis type 2 (NF2) usually presents in patients
in their early 20s with symptoms related to vestibular
schwannomas. Younger age at onset occurs in nearly 20% of
patients with NF2, however, and in these patients, non-
vestibular presentations predominate, including visual
symptoms (cataracts, retinal hamartoma, or optic nerve
sheath meningioma), cutaneous lesions (NF2 skin plaques,
cutaneous schwannomas, or hyperpigmented lesions), tran-
sient mononeuropathy of cranial nerves, seizures (often with
focal cortical dysplasia), and symptomatic spinal nerve root
Figure 1 Radiographic features of the case
(A) Aggressive growth pattern of tumors. Note
the enhancement in the left middle cerebellar
peduncle on August 12, 2016, in the region of T2-
weighted signal change. (B) T2 fluid attenuation
inversion recovery changes across time. The
earlier lesion in 2015 has enlarged and shows
enhancement. Biopsy in this region showed ne-
crosis but was negative for tumor or infection.
(C) Time course of spreading ADC changes. The
duration of depressed ADC is atypically long
compared with the phasic pattern usually seen
in acute stroke. ADC = apparent diffusion
coefficient.
GLOSSARY
ADC = apparent diffusion coefficient; CPM = central pontine myelinolysis; NF2 = neurofibromatosis type 2.
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schwannomas.1,2 We recently encountered a patient with
progressive brainstem necrosis, as shown on serial diffusion-
weighted images and by biopsy. Seven prior published cases
had marked similarities, suggesting an underrecognized syn-
drome in NF2.
Methods
We performed a detailed case review including clinical and
neuroimaging analyses, genetic testing, and brain biopsy.
Multicase analysis was undertaken to observe common fea-
tures in 16 predetermined categories.3–6
Results
Clinical data
A 25-year-old woman with a history of strabismus surgery in
childhood developed episodes of vertigo. After 6 months of
persistent symptoms, imaging revealed bilateral vestibular and
other cranial nerve schwannomas, multiple meningiomas and
a cervical cord ependymoma, as well as several small focal
white matter lesions in the corona radiata. There was a subtle,
nonenhancing focus of T2-weighted hyperintensity in the L
middle cerebellar peduncle on a December 2015 MRI, adja-
cent to a subsequent area of restricted diffusion (figure 1).
There was no family history of NF2, although the parents
were not tested or imaged. Single gene testing of
blood lymphocytes detected a germline NF2 variant, c.288_
290delCTT, which deletes a highly conserved proline residue
and is thought to inactivate merlin. A large left lumbar
schwannoma raised concern for malignant peripheral nerve
sheath tumor and was partially resected via an abdominal
approach. There was substantial blood loss requiring trans-
fusion and volume support. Ten days later, she developed
progressive slurred speech, left facial numbness, bilateral hand
weakness, and difficulty walking. Blood pressure and serum
sodium were normal. She progressed to a locked-in syndrome
over 4 days with some residual eye movements. Serial MRIs
revealed a multifocal, bilateral, spreading area of markedly
hypointense apparent diffusion coefficient (ADC) signal (0.3
× 10−3 mm2/s) in the pons and left middle cerebellar pe-
duncle (figure 1). At the site of the prior T2 signal change in
the left middle cerebral peduncle, there was subtle enhance-
ment where ADC was less decreased. Vascular imaging, in-
cluding CT angiogram and a catheter angiogram, showed
a basilar artery diameter of 3.9 mm at the mid pons and
a basilar bifurcation at the level of the dorsum sellae (figure 2,
A and B) and was midline throughout, thus not meeting
a definition of dolichoectasia.7–9 The anatomy of the basilar
artery did not change as seen 5 years later on the 2020 MRI
study. Serial ADC maps showed prolonged loss of signal over
time rather than the typical phasic pattern seen after ischemic
stroke. Perfusion maps suggested decreased cerebral blood
volume and cerebral blood flow in the lesion (data not pre-
sented). CSF showed a WBC of 5 cells per mm3 but was
otherwise normal including nucleic acid amplification tests for
viral infection. Biopsy of the left middle cerebellar peduncle in
the area of initial enhancement revealed white matter, which
varied from near-normal to necrotic. Within the latter, there
was evidence of axonal swelling, mild macrophage infiltration,
and scant lymphocytes. Luxol fast blue–Periodic acid–Schiff
stain showed focal loss of myelin staining but with some
fragments showing normal myelin. No vascular pathology was
identified. PCR analysis of tissue for infection was negative.
Fluorodeoxyglucose-PET 1 month after the onset showed
hypometabolism in the pons. Subsequent MRIs demon-
strated some persistent restricted diffusion as well as ence-
phalomalacia of the basis pontis and rapid growth of multiple
NF2-related tumors. Four years later, the patient is locked-in
except for upgaze and is deaf in both ears. Amammalian target
of rapamycin inhibitor was started in an attempt to suppress
further growth of the tumors.10,11
Syndrome features
Table 1 shows the findings of 8 cases with regard to 16 pre-
determined categories of clinical, imaging, genetic, and
pathologic features.3–6 In addition, a 2019 article from a UK
group described 2 pediatric patients, without clinical details,
who had pontine infarcts. One had renal artery stenosis and
coarctation of the aorta, and a second had vertebral artery
stenosis and a 22q microdeletion.12 Table 2 shows an analysis
of the NF2 variants reported in each case. Overall, the simi-
larities between cases are striking.
Figure 2 Vascular imaging
(A) Diameter of the basilar artery at mid pons. The maximal diameter of
3.9 mmdid not meet the 4.5-mm threshold for dolichoectasia. The course of
the basilar artery was midline. (B) Tip of the basilar artery. The basilar artery
bifurcated at the level of the dorsum sellae and thus did notmeet the criteria
for elongation. Note the persistent right fetal posterior cerebral artery.
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To summarize the data, the syndrome of brainstem necrosis
in juvenile NF2 typically occurs in teenagers without pre-
viously knownNF2 as an acute, typically monophasic event in
the midbrain or pons. Some patients have had a recent
hypoperfusion event. MRI shows markedly restricted diffu-
sion in the lesion, but vascular imaging is normal. Our case
demonstrated evolution of imaging findings and showed
some unusual features compared with acute stroke. NF2 im-
aging features are apparent at the time of diagnosis. Typical
null NF2 alterations are seen, and absence of family history in
most cases suggests a de novo mutation. Biopsy in 2 cases,
including ours, shows necrosis without small vessel pathology.
The early-onset, high number of NF2-related lesions at di-
agnosis and the subsequent rapid growth suggest an
Table 1 Features of the syndrome







Age at dx NF2, y 2, 4, 6, 7, 13, 13, 22, 25a 11.5 (4.5–18.5)
Age at brainstemevent,
y
2, 4, 7, 13, 13, 15, 22, 25a 12.6 (5.5–19.5)
Genetic alteration c.114G>A (splice donor, VUS); c.115-1G>C (null); c.169C>T (null); NF1 neg; c.288_290delCTTa;
c.447+1G>A (null); c.448-1G>A (null); frameshift, exon 12; deletion exon2
Typical null variants in NF2
De novo Y, Yb, Yb, Yb, Yb, Yb, Ya; N Usually de novo
Severity of NF2 M; S, S, S, S, S, S, S, Sa Severe
Unusual lesions for NF2 N, N, N, N, N, N; Cb Ca++, No VS, E, cauda; white matter lesionsa Occasional
Brainstemcompression
by VS at event
N, N, N, N, N, N, N, Na No
Precipitating event Diarrhea; fever, cough; menorrhagia; blood loss after pelvic surgerya; no; NR, NR, NR Yes, possibly
hypoperfusion





Midbrain MB, MB, MB
Pons P, P, P, P, P, Pa
Medulla MD
Unilateral U, U, U
Bilateral Ba
Left L, L, L, L, La
Right R, R, Ra
Clinical severity M, M, M, M; S, S, S, Sa Mild to severe
HTN at onset N, N, N, N, N, N, Na; NR, NR No
Vascular imaging Neg, Neg, Neg, Neg, Neg, Nega; narrowing left ICA; small left MCA Normal; rarely narrowed
lumen ICA or MCA
Stroke blood testing Neg, Neg, Neg, Neg, Neg, Nega; NR, NR Negative
Biopsy features Reactive astrogliosis, microglia, hyalinized large caliber vessels; necrosis, vessels normala Necrosis; vessels normal
Abbreviations: AM = acute monophasic; AP = acute progressive; B = bilateral; Cb-Ca++ = cerebellar calcification; CI = confidence interval; E = ependymoma;
HTN = hypertension; ICA = internal carotid artery; M = mild; MB = midbrain; MCA = middle cerebral artery; MD = medulla; N = no; Neg = negative; NR = not
reported; P = pons; S = severe; U = unilateral; VS = vestibular schwannoma.
a Present case.
b Likely but not explicitly stated.
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aggressive form of NF2 in these patients as is often seen in
younger patients.
Discussion
There are remarkable similarities between the cases in the
literature and our patient, and this suggests a discrete clinical
syndrome of which pediatric neurologists and stroke neurol-
ogists should be aware. The name brainstem ischemic syn-
drome in juvenile NF2 is proposed for this rare syndrome.
Our patient seems to have the most clinically devastating
course of those reported to date, and despite the similarities in
the cases, there are some distinctive features, which may be of
value. Our patient was of somewhat older age. Gradual pro-
gression over 4 days to a severe neurologic syndrome with
spreading restricted diffusion, rather than the monophasic
courses reported before, is also unusual. Perfusion imaging in
our patient showed low cerebral blood flow and blood volume
in the pons, but it was difficult to be certain that ischemia was
the cause of the perfusion changes, and the bilateral pro-
gression, the atypically long phasic course of the restricted
diffusion, and the absence of vascular findings on imaging and
biopsy argue against ischemia as the cause. The known focus
of abnormal T2-weighted hyperintensity in the left middle
cerebellar peduncle that was adjacent to the restricted diffu-
sion had enlarged at the time of presentation and showed
enhancement, and this seemed likely to represent a tumor, but
biopsy of the area did not support this. Acute vacuolization of
myelin, including that seen with central pontine myelinolysis
(CPM), can produce restricted diffusion but not usually to the
degree found in these cases. The asymmetric distribution of
lesions in the pons was also not consistent with CPM, and
there was no electrolyte abnormality. Delayed hypoxic leu-
koencephalopathy can show a long course of markedly re-
stricted diffusion, but has not been described in the brainstem,
and the preceding events in the patients here were not con-
sistent with this mechanism. An infectious process seems
unlikely given the benign CSF profile and negative PCR
testing. Finally, our patient had deletion of a highly conserved
proline rather than the truncating mutation more commonly
seen in the other cases and in patients with NF2 in general.
Nonetheless, this deletion likely produced a loss of function in
merlin in common with null mutants.
There have been rare cases in which angiographic narrowing
of the internal carotid artery,6 middle cerebral artery (with
middle cerebral artery infarct),13 vertebral artery,12 aorta,12 or
renal artery14 has been seen in NF2, leading those authors to
propose a vascular process. Although well known in NF1,
vasculopathy is not clearly recognized in young patients with
NF2 at this time.1,2,12 Progressive brainstem stroke syn-
dromes have been seen with dolichoectasia of the basilar ar-
tery in NF1.15 Our patient did not meet the criteria for
dolichoectasia. It is notable that these brainstem ischemic
events occur in such close anatomic proximity to the uniquely
selective development of vestibular schwannomas in NF2.
Given the rarity of the syndrome of brainstem ischemic syn-
drome in juvenile NF2, it is possible that a digenic process is at
work. One of the literature reports analyzed theNF1 gene and
found no alterations. Whole-exome sequencing would be
a reasonable consideration in these cases.
Acknowledgment
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Table 2 Analysis of alterations





c.114G>ANM_000268.4a Alteration within used splice
site
Pathogenic: PVS1, PM1, PM2, BP4 0% Disease causing
c.115-1G>C NM_
000268.4a
Alteration within used splice
site
Pathogenic: PVS1, PM2, PP3 0% Disease causing












Alteration within used splice
site
Pathogenic: PVS1, PM2, PP3 0% Disease causing
c.448-1G>A NM_
000268.4a
Alteration within used splice
site
Pathogenic: PVS1, PM2, PP3 0% Disease causing
Frameshift, exon 12 Truncating NA NA NA
Deletion exon 2 Truncating NA NA NA
Abbreviations: ACMG = American College of Medical Genetics; gnomAD = Genome Aggregation Database; NA = not available.
a Probable transcript but not explicitly stated in reference.
b Current case.
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